CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,043,610
- in 4 filings, $16.0M under 10b5-1 plans
Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-29 | Fairmount Funds Management LLC Director | Purchase | +24,670 | $13.63 | $336K | 1,928,503 |
| 2023-09-26 | Fairmount Funds Management LLC Director | Purchase | +30,000 | $13.15 | $395K | 1,903,833 |
| 2023-09-22 | Randhawa Simrat Chief Medical Officer | Purchase | +2,000 | $13.20 | $26K | 4,000 |
| 2023-09-21 | Randhawa Simrat Chief Medical Officer | Purchase | +2,000 | $13.20 | $26K | 2,000 |
| 2023-09-19 | Fairmount Funds Management LLC Director | Purchase | +30,000 | $13.20 | $396K | 1,873,833 |
| 2023-09-13 | Fairmount Funds Management LLC Director | Purchase | +9,367 | $11.76 | $110K | 1,843,833 |
| 2023-09-12 | Fairmount Funds Management LLC Director | Purchase | +14,887 | $10.85 | $162K | 1,834,466 |
| 2020-06-29 | Booth Bruce Director | Purchase | +1,250,000 | $8.00 | $10.0M | 1,250,000 |
| 2018-06-25 | Scadden David Director | Purchase | +6,600 | $15.00 | $99K | 228,175 |
| 2018-06-25 | GARDNER JASON See Remarks | Purchase | +400 | $15.00 | $6K | 363,212 |
Page 1 of 1 · 10 trades